eli lilly's tirzepatide is the leader in weight loss sector Lilly, maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose a Phase 3 trial, as the company moves closer to submitting Tirzepatide from Lilly may be

Hepatic miRNA profiles and thyroid hormone homeostasis in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS)

Tracking the intersection of litigation stay expiration dates and ANDA review timelines identifies the earliest possible FDA approval date for a specific generic product

Why choose this treatment

SEMA, como tratamiento de la obesidad, ha mostrado efectos nefroprotectores con disminucin del 22% del objetivo renal compuesto en el estudio SELECT33 en pacientes sin diabetes, abogando por la utilidad de SEMA en el tratamiento del sndrome cardio-reno-metablico

- Pitching products: why its key to answer why now

Additional data are needed